• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Editas Medicine Announces First Quarter 2024 Results and Business Updates

    5/8/24 7:00:00 AM ET
    $BMY
    $EDIT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BMY alert in real time by email

    Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease

    On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024

    Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines

    Strong financial position with operational runway into 2026

    CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and provided business updates.

    "We made significant progress in all three pillars of our strategy this quarter, including reni-cel, in vivo, and business development, including intellectual property," commented Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. "We entered 2024 with great momentum, and I am proud of the Editas team's significant progress toward becoming a commercial-stage company and on developing clinically differentiated, transformational medicines for people living with serious, previously untreatable diseases."

    Recent Achievements and Outlook

    Ex Vivo Hemoglobinopathies

    • Reni-cel (renizgamglogene autogedtemcel, previously EDIT-301) for Severe Sickle Cell Disease (SCD)
      • The Company has completed enrollment of the adult cohort of the Phase 1/2/3 RUBY trial for SCD and continues to dose patients.
      • The Company has enrolled multiple patients in the adolescent cohort in the RUBY trial.
      • The Company remains on-track to present a substantive clinical data set of sickle cell patients with considerable clinical follow-up in the RUBY trial in mid-2024 and further data by year-end 2024.
    • Reni-cel for Transfusion-dependent Beta Thalassemia (TDT)
      • The Company continues to enroll and dose patients in the EdiTHAL trial for TDT.
      • The Company remains on-track to present additional clinical data from the EdiTHAL trial in mid-2024 and further data by year-end 2024.

    In Vivo Medicines

    • The Company is presenting pre-clinical data later this week to support its development of transformative in vivo gene editing medicines at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting on May 9 and 10. Presentations include:
      • Oral presentation of in vivo pre-clinical data from mouse studies using lipid nanoparticle (LNP)-mediated delivery of an optimized guide RNA (gRNA) and engineered AsCas12a messenger RNA (mRNA).
      • Pre-clinical data demonstrating AsCas12a gRNA modifications that enable high-potency gene editing in multiple cell types, including in the liver, and improve gene editing outcomes in vivo, enabling the development of in vivo gene editing medicines.
      • Research on identifying potent large serine recombinases (LSRs) as a foundation to develop novel in vivo gene editing technologies for whole gene knock-in, expanding potential in vivo gene editing targets for developing medicines.
    • The Company is on track to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end.

    Other Corporate Highlights

    Business Development

    • In March 2024, Editas Medicine and Bristol Myers Squibb (NYSE:BMY) signed a two-year extension to the collaboration under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The extension also has options to further extend the collaboration for up to an additional two years.

    Intellectual Property

    • Oral Arguments held in CRISPR patent interference

      On May 7, 2024, oral arguments were held before the U.S. Court of Appeals for the Federal Circuit (CAFC) regarding an appeal of the Patent Trial and Appeal Board's (PTAB's) previous decision favoring Broad Institute (Broad) in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and Broad. A decision on the case is expected in the second half of 2024.

    Leadership

    • Gregory Whitehead named Executive Vice President and Chief Technical and Quality Officer

      Mr. Whitehead joins the executive leadership team as Chief Technical and Quality Officer (CTQO), responsible for leading the Technical Development, Technical Operations, and Quality departments as the Company advances its gene editing medicines towards biologics license applications (BLAs). Mr. Whitehead has more than 25 years of experience in the biotech industry and extensive cell and gene therapy clinical and commercial development expertise. Prior to his current role, Mr. Whitehead served as Senior Vice President of Quality at Editas Medicine. Before joining Editas Medicine, Mr. Whitehead served as Chief Quality Officer at Rubius Therapeutics, establishing quality capabilities to support first-in-human clinical trials for genetically engineered red blood cells. Earlier in his career, he served as Vice President, Quality at bluebird bio. During his tenure at bluebird bio, Mr. Whitehead scaled the organization in support of multiple gene therapy clinical trials and commercial launch in the U.S. and Europe.

    Publications

    • The New England Journal of Medicine published the findings from the Phase 1/2 BRILLIANCE trial of EDIT-101, on May 6.
      • The BRILLIANCE trial was the first in vivo CRISPR gene editing study in humans, and the study demonstrated clinical proof of concept in treatment of a rare inherited blindness, Leber Congenital Amaurosis 10, with a favorable safety profile, and preliminary efficacy signals for patients.

    First Quarter 2024 Financial Results

    Cash, cash equivalents, and marketable securities as of March 31, 2024, were $376.8 million compared to $427.1 million as of December 31, 2023. The Company expects the existing cash, cash equivalents, and marketable securities together with the near-term annual license fees and the contingent upfront payment payable under its license agreement with Vertex Pharmaceuticals, Incorporated, to fund operating expenses and capital expenditures into 2026.

    First Quarter 2024

    • For the three months ended March 31, 2024, net loss attributable to common stockholders was $62.0 million, or $0.76 per share, compared to net loss of $49.0 million, or $0.71 per share, for the same period in 2023.



    • Collaboration and other research and development revenues decreased to $1.1 million for the three months ended March 31, 2024, compared to $9.9 million for the same period in 2023. The decrease relates to the one-time sale in January 2023 of the Company's wholly owned oncology assets and related licenses.



    • Research and development expenses increased by $11.0 million to $48.8 million for the three months ended March 31, 2024, compared to $37.8 million for the same period in 2023. The increase is primarily attributable to sublicense and license payments as well as clinical and manufacturing costs related to the continued progression of the Company's reni-cel program.



    • General and administrative expenses decreased by $3.7 million to $19.3 million for the three months ended March 31, 2024, compared to $23.0 million for the same period in 2023. The decrease is primarily attributable to one-time professional service expenses related to 2023 strategic initiatives and business development activities as well as reduced legal and patent costs.

    Upcoming Events

    Editas Medicine plans to participate in the following scientific and medical conference:

    • American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

      May 7-11, 2024

      Baltimore, MD

    Editas Medicine plans to participate in the following investor events:

    • Bank of America Health Care Conference 2024

      May 14, 2024

      Las Vegas, NV
    • 2024 RBC Capital Markets Global Healthcare Conference 

      May 15, 2024

      New York, NY
    • Stifel's 2nd Annual Genetic Medicines Forum

      May 28, 2024

      Virtual

    Conference Call

    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the first quarter of 2024. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call. A live webcast of the call will also be available on the Investors section of the Editas Medicine website at www.editasmedicine.com, and a replay will be available approximately two hours after its completion.

    About Editas Medicine

    As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company's preclinical and clinical studies and its research and development programs, including establishing in vivo preclinical proof-of-concept for an undisclosed indication by year-end 2024, the timing for the Company's receipt and presentation of data from its clinical trials and preclinical studies, including presenting additional clinical data from the RUBY and EdiTHAL trials in mid-2024 and additional updates by year-end 2024, potential of, and expectations for, the Company's product candidates, the timing or likelihood of regulatory filings and approvals, the Company's expectations regarding commercial readiness, and the Company's expectations regarding cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company's product candidates, including reni-cel; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company's subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.



    EDITAS MEDICINE, INC.

    Consolidated Statement of Operations

    (amounts in thousands, except share and per share data)

    (Unaudited)

     Three Months Ended March 31,
      2024   2023 
    Collaboration and other research and development revenues$1,135  $9,851 
    Operating expenses:   
    Research and development 48,787   37,804 
    General and administrative 19,339   23,008 
    Total operating expenses 68,126   60,812 
    Operating loss (66,991)  (50,961)
    Other income, net:   
    Other income (expense), net 6   (1,584)
    Interest income, net 5,035   3,509 
    Total other income, net 5,041   1,925 
    Net loss$(61,950) $(49,036)
    Net loss per share, basic and diluted (0.76)  (0.71)
    Weighted-average common shares outstanding, basic and diluted 81,938,839   68,924,180 
            

    EDITAS MEDICINE, INC.

    Selected Consolidated Balance Sheet Items

    (amounts in thousands)

    (Unaudited)

     March 31, December 31,
     2024 2023
    Cash, cash equivalents, and marketable securities$376,776 $427,135
    Working capital 239,068  277,612
    Total assets 440,347  499,153
    Deferred revenue, net of current portion 54,204  60,667
    Total stockholders' equity 294,400  349,097
          



    Media and Investor Contact:
    Cristi Barnett
    (617) 401-0113
    [email protected] 

    Primary Logo

    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY
    $EDIT

    CompanyDatePrice TargetRatingAnalyst
    Editas Medicine Inc.
    $EDIT
    4/28/2025$3.00Buy
    H.C. Wainwright
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Editas Medicine Inc.
    $EDIT
    12/16/2024Neutral → Underweight
    Analyst
    Editas Medicine Inc.
    $EDIT
    12/13/2024Buy → Neutral
    Chardan Capital Markets
    Editas Medicine Inc.
    $EDIT
    12/13/2024Buy → Hold
    Truist
    Editas Medicine Inc.
    $EDIT
    12/13/2024$11.00 → $3.00Buy → Hold
    Stifel
    More analyst ratings

    $BMY
    $EDIT
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

      Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh

      3/13/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

      On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

      3/5/25 4:05:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BMY
    $EDIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/12/24 2:30:25 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/4/24 11:57:08 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      10/17/24 1:10:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BMY
    $EDIT
    SEC Filings

    See more
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      5/7/25 5:04:09 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bristol-Myers Squibb Company

      10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 11:45:34 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 7:11:41 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $EDIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the following upcoming investor conference in May: Bank of America Global Healthcare Conference Format: Fireside ChatDate: Tuesday, May 13Time: 5:15 p.m. PTLocation: Las Vegas, NV To access

      5/5/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to

      4/28/25 4:31:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BMY
    $EDIT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $EDIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/5/25 5:41:48 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Financial Officer Parison Amy

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:29:42 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BMY
    $EDIT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Editas Medicine with a new price target

      H.C. Wainwright initiated coverage of Editas Medicine with a rating of Buy and set a new price target of $3.00

      4/28/25 8:37:22 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $EDIT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $EDIT
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate